<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02583334</url>
  </required_header>
  <id_info>
    <org_study_id>CMUH103-REC1-138</org_study_id>
    <nct_id>NCT02583334</nct_id>
  </id_info>
  <brief_title>Acupuncture for Fibromyalgia</brief_title>
  <official_title>Clinical Efficacy of Acupuncture in Patients With Fibromyalgia: A Multi-center, Randomized, Assessor and Participant-blinded, Controlled, and Parallel-design Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China Medical University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fibromyalgia is the second most common autoimmune rheumatic diseases with clinical&#xD;
      manifestations of widespread pain, fatigue and accompanied cognitive and emotional&#xD;
      disturbances. It often associated with sleep disorders and headaches. The cardinal symptom of&#xD;
      fibromyalgia is widespread pain. Clinical observations reveal that pain in patients with&#xD;
      fibromyalgia could not simply improve by using analgesics only. Patients often use Chinese&#xD;
      medicine or acupuncture to help them to ease the pain.&#xD;
&#xD;
      The aim of this study is to investigate the efficacy of acupuncture in patients with&#xD;
      fibromyalgia. The study adapted a randomized, assessor- and participant-blinded,&#xD;
      sham-controlled, and parallel-design approach to investigate whether acupuncture can improve&#xD;
      the clinical symptoms and quality of life as well as the mechanism through laboratory&#xD;
      biochemistric and image study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 158 volunteers of patients with fibromyalgia will be recruited from the Chinese&#xD;
      medicine or Western medicine clinics in China Medical University Hospital(Taichung and other&#xD;
      affiliated branches). After diagnosis by rheumatologist, these patients will be randomized to&#xD;
      receive verum acupuncture or sham acupuncture treatment, three times a week, for 4 weeks (12&#xD;
      treatment in total). Visual analogue scale will be done for every visit. Laboratory&#xD;
      biochemistric analysis and other questionnaires including Visual Analogue Scale, Fibromyalgia&#xD;
      Impact Questionnaire, SF-36 health survey, Pittsburgh Sleep Quality Index and Beck Depression&#xD;
      Inventory-II will be completed at baseline, 2, 4 weeks after initiation of intervention&#xD;
      (complete acupuncture treatment), 4 weeks after completion of acupuncture completion (8&#xD;
      weeks). PET image examination (optional; this item depends on patients' own will) and&#xD;
      instrumental examinations including heart rate variability and traditional Chinese medicine&#xD;
      four examinations will be given before and after intervention. We expect that the efficacy of&#xD;
      verum acupuncture is superior to sham acupuncture in improving pain, fatigue, physical&#xD;
      function and quality of life. The effectiveness of acupuncture can be detected by&#xD;
      questionnaires. Moreover, we will further speculate the mechanism by analyzing laboratory and&#xD;
      image data.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fibromyalgia Impact Questionnaire</measure>
    <time_frame>0,2,4,8 week</time_frame>
    <description>Changes from baseline to midpoint、end of intervention and 4 weeks after intervention completed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SF-36 health survey</measure>
    <time_frame>0,2,4,8 week</time_frame>
    <description>Changes from baseline to midpoint、end of intervention and 4 weeks after intervention completed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pittsburgh Sleep Quality Index</measure>
    <time_frame>0,2,4,8 week</time_frame>
    <description>Changes from baseline to midpoint、end of intervention and 4 weeks after intervention completed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory-II</measure>
    <time_frame>0,2,4,8 week</time_frame>
    <description>Changes from baseline to midpoint、end of intervention and 4 weeks after intervention completed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Constitution in Chinese Medicine Questionnaire</measure>
    <time_frame>0,2,4,8 week</time_frame>
    <description>Changes from baseline to midpoint、end of intervention and 4 weeks after intervention completed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate variability</measure>
    <time_frame>0,4 week</time_frame>
    <description>Changes from baseline to the end of intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory examination: cytokines</measure>
    <time_frame>0,4 week</time_frame>
    <description>Changes from baseline to the end of intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematogram</measure>
    <time_frame>0,4 week</time_frame>
    <description>Changes from baseline to the end of intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FDG PET/CT scan</measure>
    <time_frame>0, 4-6week</time_frame>
    <description>optional examination; changes from baseline to the 4-6week of intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale</measure>
    <time_frame>0,2,4,8 week</time_frame>
    <description>Changes from baseline to midpoint、end of intervention and 4 weeks after intervention completed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TCM four examinations</measure>
    <time_frame>0,4 week</time_frame>
    <description>Changes from baseline to the end of intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver function test</measure>
    <time_frame>0,4 week</time_frame>
    <description>Changes at baseline and end of intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function test</measure>
    <time_frame>0,4 week</time_frame>
    <description>Changes from baseline to the end of intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Widespread pain index</measure>
    <time_frame>0,2,4,8 week</time_frame>
    <description>Changes from baseline to midpoint、end of intervention and 4 weeks after intervention completed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom severity scale</measure>
    <time_frame>0,2,4,8 week</time_frame>
    <description>Changes from baseline to midpoint、end of intervention and 4 weeks after intervention completed</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">158</enrollment>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>Verum Acupuncture</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After diagnosis by rheumatologist, participants will be randomized to receive verum acupuncture or sham acupuncture treatment. In the verum acupuncture group, participants will receive verum acupuncture (Device: 30# acupuncture needle) three times a week, for 4 weeks (12 treatment in total).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Acupuncture</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>After diagnosis by rheumatologist, participants will be randomized to receive verum acupuncture or sham acupuncture treatment. In the sham acupuncture group, participants will receive sham acupuncture (Device: Streitberger device) three times a week, for 4 weeks (12 treatment in total).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Verum acupuncture (30# acupuncture needle)</intervention_name>
    <description>Acupuncture will be applied by inserting acupuncture needle into acupoints (LI4, LI11, LR3, ST36, SP6, GB34)</description>
    <arm_group_label>Verum Acupuncture</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham acupuncture</intervention_name>
    <description>Streitberger device will be applied by onto acupoints (LI4, LI11, LR3, ST36, SP6, GB34). The device will not really insert the blunt needle into skin but let the participants feel like real acupuncture (Lancet 1998; 352: 364-365.).</description>
    <arm_group_label>Sham Acupuncture</arm_group_label>
    <other_name>Streitberger device</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participants met the diagnostic criteria (American College of Rheumatology, 2011) and&#xD;
             were diagnosed fibromyalgia.&#xD;
&#xD;
          2. Persisted pain for more than 50 percent of time.&#xD;
&#xD;
          3. Adult volunteers of ages between 20~75 years old.&#xD;
&#xD;
          4. Male or female genders.&#xD;
&#xD;
          5. No allergy or contraindication to stainless needles.&#xD;
&#xD;
          6. Participants understood the aim and process of the trial, agreed to participate in&#xD;
             trial as well as completed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. More than 75 or less than 20 years old.&#xD;
&#xD;
          2. Had used opioid or narcotic analgesic drugs within one month before the beginning of&#xD;
             trial.&#xD;
&#xD;
          3. Had used Pregabalin within 6 months.&#xD;
&#xD;
          4. Drug abuse.&#xD;
&#xD;
          5. Coagulation dysfunction or low platelet count in blood tests(platelet≤150000 / uL).&#xD;
&#xD;
          6. Other diagnosed rheumatoid comorbidities such as rheumatoid arthritis, systemic lupus&#xD;
             erythema, inflammatory bowel disease, autoimmune thyroiditis.&#xD;
&#xD;
          7. Participating in other clinical trials.&#xD;
&#xD;
          8. Pregnancy or lactation.&#xD;
&#xD;
          9. Severe psychological or behavioral disorders such as schizophrenia.&#xD;
&#xD;
         10. Arrhythmia patients with pacer marker.&#xD;
&#xD;
         11. Severe diseases such as myocardial infarction, severe arrhythmia,cardiac arrest,&#xD;
             chronic obstructive pulmonary disease, renal failure and cancers.&#xD;
&#xD;
         12. Limbs edema and severe skin lesions contraindicated to acupuncture.&#xD;
&#xD;
         13. Had Chinese medicine or acupuncture within two weeks prior to the beginning of trial.&#xD;
&#xD;
         14. Had not completed informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hung-Rong Yen, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>China Medical University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hung-Rong Yen, M.D., Ph.D.</last_name>
    <phone>+886-4-22052121</phone>
    <phone_ext>7508</phone_ext>
    <email>hungrongyen@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ming-Cheng Huang, M.D.</last_name>
    <phone>+886-4-22052121</phone>
    <phone_ext>1670</phone_ext>
    <email>mchuang1128@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hung-Rong Yen, M.D., Ph.D.</last_name>
      <phone>886-4-22052121</phone>
      <phone_ext>7508</phone_ext>
      <email>hungrongyen@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ming-Cheng Huang, M.D.</last_name>
      <phone>886-4-22052121</phone>
      <phone_ext>1670</phone_ext>
      <email>mchuang1128@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Hung-Rong Yen, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital-Taipei branch</name>
      <address>
        <city>Taipei</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hung-Rong Yen, M.D., Ph.D.</last_name>
      <phone>+886-4-22052121</phone>
      <phone_ext>7508</phone_ext>
      <email>hungrongyen@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Hung-Rong Yen, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>June 7, 2015</study_first_submitted>
  <study_first_submitted_qc>October 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2015</study_first_posted>
  <last_update_submitted>October 20, 2015</last_update_submitted>
  <last_update_submitted_qc>October 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acupuncture</keyword>
  <keyword>fibromyalgia</keyword>
  <keyword>rheumatism</keyword>
  <keyword>clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

